Cargando…
Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer
It is crucial to investigate the risk factors inherent in the medication process for cancer patients since improper antineoplastic drug use frequently has serious consequences. As a result, the Severity, Occurrence, and Detection rate of each potential failure mode in the drug administration process...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739421/ https://www.ncbi.nlm.nih.gov/pubmed/36497503 http://dx.doi.org/10.3390/ijerph192315428 |
_version_ | 1784847801401737216 |
---|---|
author | Lin, Shuzhi Wang, Ningsheng Ren, Biqi Lei, Shuang Feng, Bianling |
author_facet | Lin, Shuzhi Wang, Ningsheng Ren, Biqi Lei, Shuang Feng, Bianling |
author_sort | Lin, Shuzhi |
collection | PubMed |
description | It is crucial to investigate the risk factors inherent in the medication process for cancer patients since improper antineoplastic drug use frequently has serious consequences. As a result, the Severity, Occurrence, and Detection rate of each potential failure mode in the drug administration process for patients with lung cancer were scored using the Failure Mode and Effect Analysis (FMEA) model in this study. Then, the risk level of each failure mode and the direction of improvement were investigated using the Slacks-based measure data envelopment analysis (SBM-DEA) model. According to the findings, the medicine administration process for lung cancer patients could be classified into five links, with a total of 60 failure modes. The risk of failure modes for patient medication and post-medication monitoring ranked highly, with unauthorized use of traditional Chinese medicine and folk prescription and unauthorized drug addition (incorrect self-medication) ranking first (1/60); doctor prescription was also prone to errors. The study advises actively looking at ways to decrease the occurrence and difficulty of failure mode detection to continually enhance patient safety when using medications. |
format | Online Article Text |
id | pubmed-9739421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97394212022-12-11 Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer Lin, Shuzhi Wang, Ningsheng Ren, Biqi Lei, Shuang Feng, Bianling Int J Environ Res Public Health Article It is crucial to investigate the risk factors inherent in the medication process for cancer patients since improper antineoplastic drug use frequently has serious consequences. As a result, the Severity, Occurrence, and Detection rate of each potential failure mode in the drug administration process for patients with lung cancer were scored using the Failure Mode and Effect Analysis (FMEA) model in this study. Then, the risk level of each failure mode and the direction of improvement were investigated using the Slacks-based measure data envelopment analysis (SBM-DEA) model. According to the findings, the medicine administration process for lung cancer patients could be classified into five links, with a total of 60 failure modes. The risk of failure modes for patient medication and post-medication monitoring ranked highly, with unauthorized use of traditional Chinese medicine and folk prescription and unauthorized drug addition (incorrect self-medication) ranking first (1/60); doctor prescription was also prone to errors. The study advises actively looking at ways to decrease the occurrence and difficulty of failure mode detection to continually enhance patient safety when using medications. MDPI 2022-11-22 /pmc/articles/PMC9739421/ /pubmed/36497503 http://dx.doi.org/10.3390/ijerph192315428 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Shuzhi Wang, Ningsheng Ren, Biqi Lei, Shuang Feng, Bianling Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title | Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title_full | Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title_fullStr | Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title_full_unstemmed | Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title_short | Use of Failure Mode and Effects Analysis (FMEA) for Risk Analysis of Drug Use in Patients with Lung Cancer |
title_sort | use of failure mode and effects analysis (fmea) for risk analysis of drug use in patients with lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739421/ https://www.ncbi.nlm.nih.gov/pubmed/36497503 http://dx.doi.org/10.3390/ijerph192315428 |
work_keys_str_mv | AT linshuzhi useoffailuremodeandeffectsanalysisfmeaforriskanalysisofdruguseinpatientswithlungcancer AT wangningsheng useoffailuremodeandeffectsanalysisfmeaforriskanalysisofdruguseinpatientswithlungcancer AT renbiqi useoffailuremodeandeffectsanalysisfmeaforriskanalysisofdruguseinpatientswithlungcancer AT leishuang useoffailuremodeandeffectsanalysisfmeaforriskanalysisofdruguseinpatientswithlungcancer AT fengbianling useoffailuremodeandeffectsanalysisfmeaforriskanalysisofdruguseinpatientswithlungcancer |